B-intervention	0	11	Mindfulness
I-intervention	12	22	meditation
O	23	26	for
O	27	34	younger
O	35	41	breast
O	42	48	cancer
O	49	58	survivors
O	58	59	:
O	60	61	a
O	62	72	randomized
O	73	83	controlled
O	84	89	trial
O	89	90	.

O	91	104	Premenopausal
O	105	110	women
O	111	120	diagnosed
O	121	125	with
O	126	132	breast
O	133	139	cancer
O	140	143	are
O	144	146	at
O	147	151	risk
O	152	155	for
O	156	169	psychological
O	170	173	and
O	174	184	behavioral
O	185	197	disturbances
O	198	203	after
O	204	210	cancer
O	211	220	treatment
O	220	221	.

O	222	230	Targeted
O	231	244	interventions
O	245	248	are
O	249	255	needed
O	256	258	to
O	259	266	address
O	267	270	the
O	271	276	needs
O	277	279	of
O	280	284	this
O	285	295	vulnerable
O	296	301	group
O	301	302	.

O	303	307	This
O	308	318	randomized
O	319	324	trial
O	325	333	provided
O	334	337	the
O	338	343	first
O	344	354	evaluation
O	355	357	of
O	358	359	a
O	360	365	brief
O	365	366	,
O	367	378	mindfulness
O	378	379	-
O	379	384	based
O	385	397	intervention
O	398	401	for
O	402	409	younger
O	410	416	breast
O	417	423	cancer
O	424	433	survivors
O	434	442	designed
O	443	445	to
O	446	452	reduce
O	453	459	stress
O	459	460	,
O	461	471	depression
O	471	472	,
O	473	476	and
O	477	489	inflammatory
O	490	498	activity
O	498	499	.

B-eligibility	500	505	Women
I-eligibility	506	515	diagnosed
I-eligibility	516	520	with
I-eligibility	521	526	early
I-eligibility	527	532	stage
I-eligibility	533	539	breast
I-eligibility	540	546	cancer
I-eligibility	547	549	at
I-eligibility	550	552	or
I-eligibility	553	559	before
I-eligibility	560	563	age
I-eligibility	564	566	50
I-eligibility	567	570	who
I-eligibility	571	574	had
I-eligibility	575	584	completed
I-eligibility	585	591	cancer
I-eligibility	592	601	treatment
O	602	606	were
O	607	615	randomly
O	616	624	assigned
O	625	627	to
O	628	629	a
O	630	631	6
O	631	632	-
O	632	636	week
O	637	644	Mindful
O	645	654	Awareness
O	655	664	Practices
O	665	666	(
O	666	670	MAPS
O	670	671	)
O	672	684	intervention
O	685	690	group
O	691	692	(
O	692	693	n
O	694	695	=
B-intervention-participants	696	698	39
O	698	699	)
O	700	702	or
O	703	705	to
O	706	707	a
B-control	708	712	wait
I-control	712	713	-
I-control	713	717	list
I-control	718	725	control
I-control	726	731	group
O	732	733	(
O	733	734	n
O	735	736	=
B-control-participants	737	739	32
O	739	740	)
O	740	741	.

O	742	754	Participants
O	755	764	completed
O	765	779	questionnaires
O	780	786	before
O	787	790	and
O	791	796	after
O	797	800	the
O	801	813	intervention
O	814	816	to
O	817	823	assess
B-outcome-Measure	824	830	stress
I-outcome-Measure	831	834	and
I-outcome-Measure	835	845	depressive
I-outcome-Measure	846	854	symptoms
O	855	856	(
O	856	863	primary
O	864	872	outcomes
O	872	873	)
O	874	876	as
O	877	881	well
O	882	884	as
B-outcome-Measure	885	893	physical
I-outcome-Measure	894	902	symptoms
O	902	903	,
B-outcome-Measure	904	910	cancer
I-outcome-Measure	910	911	-
I-outcome-Measure	911	918	related
I-outcome-Measure	919	927	distress
O	927	928	,
O	929	932	and
B-outcome-Measure	933	941	positive
I-outcome-Measure	942	950	outcomes
O	950	951	.

O	952	957	Blood
O	958	965	samples
O	966	970	were
O	971	980	collected
O	981	983	to
O	984	991	examine
O	992	999	genomic
O	1000	1003	and
O	1004	1015	circulating
O	1016	1023	markers
O	1024	1026	of
O	1027	1039	inflammation
O	1039	1040	.

O	1041	1053	Participants
O	1054	1058	also
O	1059	1068	completed
O	1069	1083	questionnaires
O	1084	1086	at
O	1087	1088	a
O	1089	1090	3
O	1090	1091	-
O	1091	1096	month
O	1097	1103	follow
O	1103	1104	-
O	1104	1106	up
O	1107	1117	assessment
O	1117	1118	.

O	1119	1121	In
O	1122	1128	linear
O	1129	1134	mixed
O	1135	1141	models
O	1141	1142	,
O	1143	1146	the
O	1147	1151	MAPS
O	1152	1164	intervention
O	1165	1168	led
O	1169	1171	to
O	1172	1183	significant
O	1184	1194	reductions
O	1195	1197	in
B-outcome	1198	1207	perceived
I-outcome	1208	1214	stress
O	1215	1216	(
O	1216	1217	P
O	1218	1219	=
O	1220	1221	.
O	1221	1224	004
O	1224	1225	)
O	1226	1229	and
O	1230	1238	marginal
O	1239	1249	reductions
O	1250	1252	in
B-outcome	1253	1263	depressive
I-outcome	1264	1272	symptoms
O	1273	1274	(
O	1274	1275	P
O	1276	1277	=
O	1278	1279	.
O	1279	1282	094
O	1282	1283	)
O	1283	1284	,
O	1285	1287	as
O	1288	1292	well
O	1293	1295	as
O	1296	1307	significant
O	1308	1318	reductions
O	1319	1321	in
B-outcome	1322	1337	proinflammatory
I-outcome	1338	1342	gene
I-outcome	1343	1353	expression
O	1354	1355	(
O	1355	1356	P
O	1357	1358	=
O	1359	1360	.
O	1360	1363	009
O	1363	1364	)
O	1365	1368	and
B-outcome	1369	1381	inflammatory
I-outcome	1382	1391	signaling
O	1392	1393	(
O	1393	1394	P
O	1395	1396	=
O	1397	1398	.
O	1398	1401	001
O	1401	1402	)
O	1403	1405	at
O	1406	1422	postintervention
O	1422	1423	.

O	1424	1436	Improvements
O	1437	1439	in
O	1440	1449	secondary
O	1450	1458	outcomes
O	1459	1467	included
O	1468	1475	reduced
B-outcome	1476	1483	fatigue
O	1483	1484	,
B-outcome	1485	1490	sleep
I-outcome	1491	1502	disturbance
O	1502	1503	,
O	1504	1507	and
B-outcome	1508	1517	vasomotor
I-outcome	1518	1526	symptoms
O	1527	1530	and
O	1531	1540	increased
O	1541	1546	peace
O	1547	1550	and
O	1551	1558	meaning
O	1559	1562	and
O	1563	1571	positive
O	1572	1578	affect
O	1579	1580	(
O	1580	1581	P
O	1582	1583	<
O	1584	1585	.
O	1585	1587	05
O	1588	1591	for
O	1592	1595	all
O	1595	1596	)
O	1596	1597	.

O	1598	1610	Intervention
O	1611	1618	effects
O	1619	1621	on
O	1622	1635	psychological
O	1636	1639	and
O	1640	1650	behavioral
O	1651	1659	measures
O	1660	1664	were
O	1665	1668	not
O	1669	1679	maintained
O	1680	1682	at
O	1683	1686	the
O	1687	1688	3
O	1688	1689	-
O	1689	1694	month
O	1695	1701	follow
O	1701	1702	-
O	1702	1704	up
O	1705	1715	assessment
O	1715	1716	,
O	1717	1725	although
O	1726	1736	reductions
O	1737	1739	in
O	1740	1746	cancer
O	1746	1747	-
O	1747	1754	related
O	1755	1763	distress
O	1764	1768	were
O	1769	1777	observed
O	1778	1780	at
O	1781	1785	that
O	1786	1796	assessment
O	1796	1797	.

O	1798	1799	A
O	1800	1805	brief
O	1805	1806	,
O	1807	1818	mindfulness
O	1818	1819	-
O	1819	1824	based
O	1825	1837	intervention
O	1838	1850	demonstrated
O	1851	1862	preliminary
O	1863	1868	short
O	1868	1869	-
O	1869	1873	term
O	1874	1882	efficacy
O	1883	1885	in
O	1886	1894	reducing
O	1895	1901	stress
O	1901	1902	,
O	1903	1913	behavioral
O	1914	1922	symptoms
O	1922	1923	,
O	1924	1927	and
O	1928	1943	proinflammatory
O	1944	1953	signaling
O	1954	1956	in
O	1957	1964	younger
O	1965	1971	breast
O	1972	1978	cancer
O	1979	1988	survivors
O	1988	1989	.
